---

Essential Cardiac Markers

---

1. Cardiac Troponins (cTnI and cTnT) - Gold Standard

• Current ESC/ACC guidelines recommend troponin as the only biomarker for diagnosing acute MI. CK-MB is used only when troponin is unavailable.
• hs-cTn assays can reclassify roughly 30% of UA patients to NSTEMI due to higher sensitivity.
• Accelerated diagnostic pathways using hs-cTn can rule out NSTEMI in as little as 1 hour.
• A rise-and-fall pattern (delta troponin) is needed to distinguish acute MI from chronic/non-ischemic elevation.
• Troponin is not specific for the cause of injury - it can be elevated in pulmonary embolism, myocarditis, sepsis, stroke, renal failure, and many other conditions (see causes table below).

• Cardiac: heart failure, myocarditis, pericarditis, aortic dissection, Takotsubo (apical ballooning syndrome)
• Neurological: stroke, subarachnoid hemorrhage
• Pulmonary: PE, ARDS
• Systemic: sepsis, rhabdomyolysis, CKD/ESRD, hypothyroidism
• Drugs: chemotherapy, colchicine, carbon monoxide

---

2. Creatine Kinase-MB (CK-MB)

---

3. B-type Natriuretic Peptide (BNP) and NT-proBNP

---

4. Myoglobin

---

5. Lactate Dehydrogenase (LDH) and LDH Isoforms

---

6. Aspartate Aminotransferase (AST)

---

Comparative Summary Table

---

Key Clinical Principles

1. Serial sampling is required for troponin - a rise-and-fall pattern distinguishes acute MI from chronic elevation. Serial measurement at 0h, 1h, or 3h depending on protocol.
2. Troponin is preferred for all ACS - CK-MB is only a backup when troponin assays are unavailable.
3. BNP/NT-proBNP are used for heart failure, not ischemia.
4. Context matters - an isolated elevated troponin without symptoms or ECG changes requires careful interpretation before labeling it an MI.
5. In ESRD patients, baseline troponin is often elevated due to LV hypertrophy and microvascular disease; a dynamic rise of ≥20% from baseline is required to diagnose MI.

---

Complete List of All Cardiac Markers

---

CATEGORY 1 - Markers of Myocardial Necrosis (Cell Death)

1. Cardiac Troponins I and T (cTnI / cTnT) - GOLD STANDARD

• Source: Sarcomeric proteins of the cardiac contractile apparatus (myofilaments); small amounts also in cytosol
• Function: Regulate actin-myosin interaction in muscle contraction
• Rises: 3-6 hours post-MI
• Peaks: 12-24 hours
• Duration: 7-14 days
• Specificity: Very high - nearly entirely cardiac in origin
• Use: Primary marker for diagnosing MI; risk stratification in ACS/NSTE-ACS
• Key point: Even minor elevations are independently associated with adverse outcomes; does not identify the cause of myocardial injury

2. High-Sensitivity Troponin (hs-cTnI / hs-cTnT)

• Same molecule as above but detected by more analytically precise assays
• Rises: Detectable as early as 1-2 hours
• Advantage: Superior sensitivity at low concentrations; can rule in/out MI in 1 hour (ESC 0h/1h algorithm)
• Impact: Reclassifies ~30% of UA patients to NSTEMI; detectable in virtually 100% of healthy individuals at some concentration
• Limitation: More false positives; requires delta (serial change) interpretation

---

3. Creatine Kinase-MB (CK-MB)

• Source: Cardiac muscle (predominant source of MB isoform); also small amounts in skeletal muscle (especially pelvic musculature)
• Rises: 3-4 hours post-MI
• Peaks: 18-24 hours
• Normalizes: 48-72 hours
• Advantage: Faster return to baseline makes it useful for detecting reinfarction after an initial MI
• Limitation: Lower cardiac specificity than troponin; elevated in rhabdomyolysis, myositis, muscular dystrophy, vigorous exercise
• Current status: Second-line only - used when troponin is unavailable

---

4. Creatine Kinase Total (CK / CPK)

• Source: Skeletal muscle, cardiac muscle, brain, kidney, GI tract
• Rises: 4-8 hours
• Peaks: 24 hours
• Normalizes: 3-4 days
• Specificity: Very low - non-specific for cardiac tissue
• Use: Rarely used alone for cardiac diagnosis; measured alongside CK-MB

---

5. Myoglobin

• Source: Both cardiac and skeletal muscle (identical immunologically - cannot be distinguished)
• Molecular weight: 17 kDa (small, rapidly diffuses into bloodstream)
• Rises: 1-2 hours (earliest rising marker)
• Peaks: 5-7 hours
• Normalizes: Within 24 hours
• Advantage: Earliest marker; was used for very early rule-out
• Limitation: Not cardiac-specific; elevated in any skeletal muscle injury, trauma, vigorous exercise, renal failure (reduced clearance)
• Current status: Largely obsolete; replaced by hs-cTn

---

6. Lactate Dehydrogenase (LDH) / LDH Isoenzymes

• Source: Multiple tissues; LDH-1 predominates in cardiac muscle
• Rises: 24-48 hours post-MI
• Peaks: 3-6 days
• Duration: Elevated up to 7-14 days
• Diagnostic pattern: LDH-1 > LDH-2 ("flipped" ratio) = historically diagnostic of MI
• Historical use: Used when patients presented >24-48h after onset when CK-MB had already normalized
• Current status: Replaced by troponin in modern practice

---

7. Aspartate Aminotransferase (AST / SGOT)

• Source: Liver, heart, skeletal muscle, brain, kidney
• Rises: 8-12 hours
• Peaks: 18-36 hours
• Normalizes: 3-4 days
• Limitation: Very low cardiac specificity; the AST-to-ALT ratio helps differentiate cardiac vs. hepatic pathology
• Current status: Historical only; no longer used as a cardiac marker

---

8. Carbonic Anhydrase III (CA-III)

• Source: Skeletal muscle-specific; absent in cardiac tissue
• Use: Used as a corrective marker - if CA-III is elevated alongside CK-MB or myoglobin, the elevation is more likely skeletal in origin, improving cardiac specificity
• Status: Research/adjunctive marker

---

CATEGORY 2 - Markers of Myocardial Ischemia (Without Necrosis)

9. Ischemia-Modified Albumin (IMA)

• Mechanism: During myocardial ischemia, free radicals and metal ions modify the N-terminus of serum albumin, reducing its ability to bind cobalt (detected by the albumin cobalt binding test - FDA approved)
• Rises: Within minutes of ischemia onset; even before myocyte necrosis
• Normalizes: 6-12 hours
• Advantage: Can detect ischemia before troponin rises - the "pre-necrosis" window
• Limitation: Non-specific; elevated in liver disease, infections, cancer
• Use: Adjunctive, not primary; not recommended for routine ED use

---

10. Heart-Type Fatty Acid-Binding Protein (H-FABP)

• Source: Small cytoplasmic protein abundant in cardiomyocytes
• Rises: Very early (1-2 hours), similar to myoglobin but more cardiac-specific
• Advantage: More cardiac-specific than myoglobin; rises earlier than CK-MB
• Use: Investigated as an early ACS marker and for reinfarction detection
• Status: Research/emerging; not in routine clinical use

---

11. Unbound Free Fatty Acids / Whole Blood Choline

• Source: Membrane phospholipid breakdown products released during ischemia
• Status: Investigational markers of ischemia; not clinically deployed

---

CATEGORY 3 - Markers of Hemodynamic Stress / Heart Failure

12. B-type Natriuretic Peptide (BNP)

• Source: Predominantly cardiac ventricles (not the brain, despite the name); also atria to a lesser extent
• Trigger: Released in response to ventricular wall stretch (volume/pressure overload)
• BNP >100 pg/mL: Supports diagnosis of heart failure
• BNP <100 pg/mL: Largely rules out HF
• Primary uses:
  • Diagnosis and severity assessment of heart failure
  • Prognostic marker in ACS (elevated BNP = higher short-term mortality)
  • Monitoring HF therapy response
• Limitation: Elevated in PE, AF, ESRD, RV strain, aging

13. NT-proBNP (N-terminal Pro-BNP)

• Mechanism: Inactive cleavage fragment from the same BNP precursor (pro-BNP)
• Half-life: Longer than BNP (~2 hours vs. ~20 minutes for BNP) - remains elevated longer
• Cutoffs: Age-adjusted:
  • <50 years: >450 pg/mL suggests HF
  • 50-75 years: >900 pg/mL suggests HF

  • 75 years: >1800 pg/mL suggests HF

• Preferred in: Renal patients, serial monitoring
• Note: In ESRD patients on hemodialysis, natriuretic peptides are chronically elevated due to LV hypertrophy; serial changes are more meaningful than absolute values

14. Atrial Natriuretic Peptide (ANP) / MR-proANP

• Source: Cardiac atria in response to atrial stretch
• Use: Less widely used than BNP; MR-proANP (mid-regional fragment) is more stable and used in some European HF protocols
• Status: Adjunctive; not widely available in routine clinical practice

---

CATEGORY 4 - Inflammatory / Plaque Instability Markers

15. High-Sensitivity C-Reactive Protein (hs-CRP)

• Source: Liver (acute-phase reactant); released in response to systemic inflammation
• Use:
  • Long-term cardiovascular risk prediction in healthy individuals (primary prevention)
  • hs-CRP >2-3 mg/L = elevated cardiovascular risk
  • Used in conjunction with cholesterol scores (e.g., Reynolds Risk Score)
• Limitation: Non-specific; elevated in any infection, autoimmune disease, trauma
• NOT recommended for acute ED evaluation of ACS

16. Myeloperoxidase (MPO)

• Source: Abundant leukocyte enzyme found in vulnerable/ruptured coronary plaques
• Mechanism: Reflects oxidative stress and active plaque inflammation
• Key finding: Elevated MPO predicts short-term adverse cardiac events even when troponin is negative and there is no evidence of necrosis
• Use: Identifies plaque vulnerability/instability before rupture
• Status: Not yet in routine ED use; primarily investigational/research

17. Interleukin-6 (IL-6)

• Source: Inflammatory cytokine from macrophages and vascular endothelial cells
• Role: Mediates systemic inflammation in atherosclerosis and post-MI
• Use: Research marker; elevated levels predict cardiovascular events
• Status: Not routinely used clinically

18. Pregnancy-Associated Plasma Protein A (PAPP-A)

• Source: Metalloproteinase produced in atherosclerotic plaques
• Role: Activates IGF-1; marker of plaque instability
• Use: Studied as an early ACS marker (rises before troponin in some studies); also a prenatal screening marker
• Status: Investigational for cardiac use

---

CATEGORY 5 - Adhesion Molecules / Endothelial Markers

19. Vascular Cell Adhesion Molecule (VCAM-1)

20. Intercellular Adhesion Molecule (ICAM-1)

21. E-Selectin

22. P-Selectin

• Mechanism: Expressed on activated endothelial cells and platelets during atherosclerotic inflammation; facilitate leukocyte trafficking into plaques
• Use: Studied as markers of vascular inflammation and ACS risk
• Status: Research only; current evidence does not support ED use

---

CATEGORY 6 - Novel / Emerging Markers

23. Copeptin

• Source: C-terminal fragment of arginine vasopressin (AVP) precursor; released with AVP during physiological stress
• Use: Rises very rapidly with any acute stress including MI; used as an early rule-out marker in combination with troponin
• Key property: A normal copeptin + negative troponin at presentation has high negative predictive value for MI
• Status: Used in some European protocols; FDA approved in some formulations; not widely used in the US

24. ST2 (Soluble ST2)

• Source: Soluble decoy receptor for interleukin-33 (IL-33); reflects myocardial stress, fibrosis, and hypertrophy
• Use: Risk stratification and prognosis in heart failure; elevated ST2 = worse outcomes
• Advantage: Not significantly affected by age, BMI, or renal function (unlike BNP)
• Status: Approved for use in heart failure prognosis; used alongside BNP

25. Galectin-3

• Source: Beta-galactoside-binding lectin secreted by activated macrophages; marker of cardiac fibrosis and remodeling
• Use: Prognosis in heart failure; predicts fibrotic progression
• Status: FDA approved as a prognostic aid in HF; used alongside BNP/NT-proBNP

26. Growth Differentiation Factor-15 (GDF-15)

• Source: Member of TGF-beta family; released from cardiac tissue under oxidative stress, inflammation, and injury
• Use: Risk stratification in ACS and heart failure; elevated GDF-15 = increased mortality risk
• Status: Emerging marker; not yet in routine clinical use

27. MicroRNAs (miR-1, miR-133, miR-208, miR-499)

• Source: Small non-coding RNA molecules released from damaged cardiomyocytes
• Use: Highly cardiac-specific (miR-208 and miR-499 are almost exclusively cardiac); being studied for early MI detection and HF prognosis
• Advantage: Potentially more specific than troponin for cardiac origin
• Status: Research only; not clinically available yet

28. Trimethylamine N-oxide (TMAO)

• Source: Gut microbiome metabolite from dietary choline and carnitine
• Use: Elevated TMAO levels associated with increased risk of major adverse cardiovascular events (MACE)
• Status: Emerging research marker; not in routine clinical use

29. Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)

• Source: Enzyme produced by inflammatory cells within atherosclerotic plaques; cleaves oxidized phospholipids
• Use: Marker of plaque inflammation; predicts cardiovascular events independent of LDH and CRP
• Status: FDA approved for cardiovascular risk assessment; used in primary prevention risk stratification

30. Pentraxin-3 (PTX3)

• Source: Long-chain pentraxin produced locally in the vessel wall (unlike CRP which is hepatic)
• Use: More tissue-specific marker of vascular inflammation than CRP; studied in ACS and HF
• Status: Investigational

---

Summary Table - All Cardiac Markers

---

Typical Troponin Rise-and-Fall Pattern After AMI

---

Current Hierarchy in Clinical Practice

For ACUTE MI DIAGNOSIS:
  hs-Troponin (first choice)
  → CK-MB (if troponin unavailable)
  → [Myoglobin, LDH, AST: obsolete]

For HEART FAILURE:
  BNP / NT-proBNP (first choice)
  → ST2 / Galectin-3 (prognostic adjuncts)

For CARDIOVASCULAR RISK (asymptomatic):
  hs-CRP → Lp-PLA2 → Lipoprotein(a)

For PLAQUE INSTABILITY (pre-necrosis):
  IMA → Myeloperoxidase → Copeptin (adjunctive)
  [None currently recommended for routine ED use]

---

Normal Reference Values of All Cardiac Markers

Important note: Reference ranges vary by laboratory, assay manufacturer, patient sex, age, and renal function. Always interpret results in relation to your specific laboratory's reference range. The values below represent widely accepted standard ranges.

---

MARKERS OF MYOCARDIAL NECROSIS

1. Cardiac Troponin I (cTnI)

2. Cardiac Troponin T (cTnT)

3. High-Sensitivity Troponin (hs-cTn)

The ESC/ACC criteria for MI: at least one value above the 99th percentile URL plus a rising and/or falling pattern on serial testing.

---

4. CK-MB (Creatine Kinase-MB)

---

5. Total CK (Creatine Kinase)

---

6. Myoglobin

---

7. LDH (Lactate Dehydrogenase) - Total

---

8. AST (Aspartate Aminotransferase)

---

MARKERS OF HEMODYNAMIC STRESS / HEART FAILURE

9. BNP (B-type Natriuretic Peptide)

BNP < 100 pg/mL has a high negative predictive value for ruling out HF in an acutely dyspneic patient.

---

10. NT-proBNP (N-terminal Pro-BNP)

NT-proBNP has a longer half-life (~120 min) than BNP (~20 min), so levels are generally higher. Adjust for renal function (eGFR < 60 mL/min raises values significantly).

---

INFLAMMATORY / RISK MARKERS

11. hs-CRP (High-Sensitivity C-Reactive Protein)

---

EMERGING MARKERS (Reference Ranges Where Available)

12. Myeloperoxidase (MPO)

13. Copeptin

14. H-FABP (Heart-type Fatty Acid-Binding Protein)

15. IMA (Ischemia-Modified Albumin)

---

Quick Reference Summary Card

---

Key Clinical Notes on Interpretation

1. Troponin is the only biomarker for diagnosing MI per current ESC/ACC/AHA guidelines - a value above the 99th percentile URL with a rise-and-fall pattern is required.
2. BNP/NT-proBNP are affected by age, sex, BMI, and renal function - always use age-adjusted cutoffs for NT-proBNP.
3. CK-MB relative index ≥ 2.5% (CK-MB/total CK × 100) improves specificity for cardiac vs. skeletal muscle source.
4. LDH flipped pattern (LDH-1 > LDH-2) is historically significant but no longer used in modern practice.
5. Myoglobin is essentially absent from normal serum - any detectable level suggests muscle injury (cardiac or skeletal).
6. In ESRD/dialysis patients: baseline troponin, BNP, and NT-proBNP are chronically elevated - a delta rise ≥ 20% is required to diagnose acute MI.
7. hs-CRP > 10 mg/L more likely reflects active infection or inflammation and loses its value for cardiac risk stratification in that setting.